Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2023 ASCO Annual Meeting was a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care, highlighting the latest innovations in cancer research and education.
View all videos

ASCO 2023

American Society of Clinical Oncology
02–06 June 2023 | Chicago, IL

ASCO 2023

American Society of Clinical Oncology
02–06 June 2023 | Chicago, IL
The 2023 ASCO Annual Meeting was a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care, highlighting the latest innovations in cancer research and education.
View all videos

Latest videos

View all videos
1:08
ZUMA-7: overall survival benefit of axi-cel over SOC in second-line LBCL
Nirav Niranjan Shah • 4 Jun 2023
2:25
CARTITUDE-1 final results: cilta-cel in heavily pretreated patients with R/R myeloma
Yi Lin • 4 Jun 2023
1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
4:45
Safety and efficacy of obe-cel in R/R adult B-ALL: results of the pivotal FELIX study
Claire Roddie • 3 Jun 2023

Multiple Myeloma

View all
5:54
RedirecTT-1 results: teclistamab + talquetamab in R/R multiple myeloma
Yael Cohen • 4 Jun 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Lymphoma

View all
2:21
The role of molecular subtyping in DLBCL and implications for treatment decisions
Manali Kamdar • 3 Jun 2023
1:31
Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCL
Tycel Phillips • 4 Jun 2023

Myeloproliferative neoplasms

View all
2:26
ACE-536-MF-001 update: luspatercept for the treatment of anemia in myelofibrosis
Aaron Gerds • 5 Jun 2023
1:24
EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia
Lucia Masarova • 8 Jun 2023

Leukemia

View all
1:12
Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL
William Wierda • 10 Jun 2023
2:00
Phase I study of CD5 CAR-T therapy manufactured with TKIs in R/R T-ALL
LaQuisa Hill • 2 Jun 2023

CAR-T & Cellular Therapy

View all
3:49
Strategies to improve cost & access to CAR-T therapy
Edward Cliff • 3 Jun 2023
1:53
PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma
Adam Sperling • 4 Jun 2023

Trial Updates

View all
4:36
COMMANDS: luspatercept versus epoetin alfa in LR-MDS-associated anemia – results & caveats
Anand Patel • 6 Jun 2023
4:41
ASCO 2023 rare lymphoma highlights: JACKPOT8, IELSG37, and mogamulizumab + CHOP in ATL
Neha Mehta-Shah • 5 Jun 2023
The content of VJHemOnc is intended for healthcare professionals